FSD PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.66 CAD | 0.00% |
|
+4.76% | -45.00% |
| Apr. 25 | FSD Pharma Says Celly Nutrition Partners with Six+One for US Launch of Dietary Supplement | MT |
| Apr. 08 | FSD Pharma Receives Nasdaq Non-Compliance Notice | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 286.6 | 42.84 | 29.94 | 42.22 | 29.53 | 35.64 |
| Enterprise Value (EV) 2 | 265.5 | 37.02 | 12.92 | 7.354 | 13.07 | 32.47 |
| P/E ratio | -12.6 x | -0.74 x | -0.59 x | -1.03 x | -1.26 x | -2 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 3,229 x | 167 x | - | - | - | - |
| EV / Revenue | 2,991 x | 144 x | - | - | - | - |
| EV / EBITDA | -15.6 x | -1.11 x | -0.5 x | -0.25 x | -0.57 x | -1.94 x |
| EV / FCF | -589 x | -29.6 x | -0.94 x | -0.9 x | -4.75 x | -2.09 x |
| FCF Yield | -0.17% | -3.37% | -107% | -111% | -21% | -47.8% |
| Price to Book | 5.63 x | 0.9 x | 0.82 x | 0.78 x | 0.97 x | 2.69 x |
| Nbr of stocks (in thousands) | 6,834 | 7,833 | 19,162 | 40,437 | 38,504 | 39,377 |
| Reference price 3 | 41.94 | 5.470 | 1.562 | 1.044 | 0.7670 | 0.9052 |
| Announcement Date | 5/3/19 | 3/3/20 | 3/16/21 | 3/31/22 | 3/31/23 | 3/29/24 |
1USD in Million2CAD in Million3USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.0888 | 0.2571 | - | - | - | - |
| EBITDA 1 | -16.98 | -33.33 | -25.95 | -29.71 | -23.01 | -16.73 |
| EBIT 1 | -17.16 | -36.43 | -29.84 | -33.74 | -27.43 | -19.23 |
| Operating Margin | -19,330.61% | -14,168.29% | - | - | - | - |
| Earnings before Tax (EBT) 1 | -22.71 | -52.01 | -28.45 | -33.94 | -26.7 | -18.23 |
| Net income 1 | -22.71 | -52.01 | -31.8 | -35.29 | -23.61 | -17.9 |
| Net margin | -25,585.69% | -20,230.8% | - | - | - | - |
| EPS 2 | -3.318 | -7.371 | -2.640 | -1.010 | -0.6095 | -0.4522 |
| Free Cash Flow 1 | -0.4511 | -1.249 | -13.8 | -8.189 | -2.751 | -15.51 |
| FCF margin | -508.17% | -485.95% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/3/19 | 3/3/20 | 3/16/21 | 3/31/22 | 3/31/23 | 3/29/24 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 21.1 | 5.82 | 17 | 34.9 | 16.5 | 3.17 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -0.45 | -1.25 | -13.8 | -8.19 | -2.75 | -15.5 |
| ROE (net income / shareholders' equity) | -71.6% | -105% | -78.4% | -75.1% | -63.1% | -83.9% |
| ROA (Net income/ Total Assets) | -32.3% | -41.3% | -43.8% | -40.2% | -33.8% | -43% |
| Assets 1 | 70.37 | 125.9 | 72.62 | 87.78 | 69.8 | 41.61 |
| Book Value Per Share 2 | 7.460 | 6.100 | 1.890 | 1.340 | 0.7900 | 0.3400 |
| Cash Flow per Share 2 | 3.090 | 1.000 | 0.9100 | 0.8700 | 0.4400 | 0.0700 |
| Capex 1 | 4.03 | 0.53 | - | - | 0.11 | - |
| Capex / Sales | 4,543.37% | 207.75% | - | - | - | - |
| Announcement Date | 5/3/19 | 3/3/20 | 3/16/21 | 3/31/22 | 3/31/23 | 3/29/24 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -45.00% | 19.34M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +0.61% | 22.15B | |
| -17.37% | 21.02B | |
| -8.61% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- HUGE Stock
- Financials FSD Pharma Inc.
